26.07 08:00 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine |
18.07 09:15 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine |
01.07 08:30 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan |
28.06 16:27 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa |
26.06 10:25 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA |
17.06 16:21 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate |
31.05 16:33 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine |
30.05 13:30 | dpa-AFX: GNW-Adhoc: Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa |
08.05 07:37 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Announces Interim Results for the First Three Months of 2024 |
29.04 21:30 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve |
29.04 15:03 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate |
02.04 08:00 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S. |
13.03 13:29 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland |
12.03 17:30 | dpa-AFX: GNW-Adhoc: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such |
06.03 07:39 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Publishes Annual Report 2023 |
23.02 07:35 | dpa-AFX: GNW-Adhoc: Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency |
21.02 08:13 | dpa-AFX: GNW-Adhoc: Bavarian Nordic delivered record financial results in 2023 |
22.11 18:00 | dpa-AFX: GNW-Adhoc: Bavarian Nordic to hold Capital Markets Days in February 2024 |
16.11 07:37 | dpa-AFX: GNW-Adhoc: Bavarian Nordic Announces Interim Results for the First Nine Months of 2023 |
25.10 20:03 | dpa-AFX: GNW-Adhoc: Bavarian Nordic's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk |
|